Layn(SZ:002166) Zhong Guo Jing Ji Wang·2025-12-24 03:22Core Viewpoint - The stock of Rhine Biotech (002166.SZ) resumed trading and hit the daily limit, closing at 9.57 yuan, a 10.00% increase, following the announcement of a change in control and related agreements [1]. Group 1: Control Change Agreements - The controlling shareholder Qin Benjun signed several agreements with Guangzhou Defu Nutrition Investment Partnership, including a framework agreement for control change and a share transfer agreement, transferring 60 million shares (8.09% of total shares) and relinquishing voting rights for 189,141,310 shares (25.50% of total shares) [2][8]. - After the transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers of the company [4][8]. Group 2: Share Transfer Details - The share transfer price was set at 10.76 yuan per share, totaling 645.6 million yuan, inclusive of all applicable taxes [3]. - Post-transfer, Qin Benjun will retain voting rights for 22,248,282 shares (3.00% of total shares) [2][8]. Group 3: Asset Purchase and Fundraising - The company plans to issue shares to acquire 80% of Beijing Jinkangpu's equity from Defu Jinkangpu and Xiamen Defu Jinkangpu, and to raise funds for purchasing additional shares from individual shareholders [4][6]. - The final transaction price for the assets will be based on an evaluation report from a qualified asset appraisal agency [5]. - The company aims to expand its business into the nutritional fortifier sector, enhancing its operational stability and risk resistance [6][7]. Group 4: Financial Performance of Target Company - For the fiscal year 2024 and the first three quarters of 2025, Beijing Jinkangpu reported revenues of 431.82 million yuan and 337.65 million yuan, respectively, with net profits of 70.27 million yuan and 40.33 million yuan, and a return on equity of 14.33% and 7.60% [7].